ArQule, Inc. (NASDAQ:ARQL)’s share price rose 12.1% during trading on Thursday . The stock traded as high as $1.98 and last traded at $1.95. Approximately 607,400 shares changed hands during trading, an increase of 21% from the average daily volume of 503,300 shares. The stock had previously closed at $1.74.

ARQL has been the topic of several analyst reports. Zacks Investment Research upgraded shares of ArQule from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a report on Friday, September 8th. ValuEngine upgraded shares of ArQule from a “strong sell” rating to a “sell” rating in a report on Friday, November 17th. Finally, Needham & Company LLC upgraded shares of ArQule from a “hold” rating to a “buy” rating in a report on Thursday, December 14th.

The stock has a market cap of $161.15, a price-to-earnings ratio of -4.63 and a beta of 1.38. The company has a debt-to-equity ratio of 2.33, a quick ratio of 3.45 and a current ratio of 3.45.

ArQule (NASDAQ:ARQL) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02. During the same quarter in the prior year, the company earned ($0.08) EPS. equities research analysts forecast that ArQule, Inc. will post -0.39 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the stock. Curbstone Financial Management Corp grew its holdings in ArQule by 100.0% during the 3rd quarter. Curbstone Financial Management Corp now owns 104,572 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 52,286 shares during the last quarter. Northern Trust Corp grew its holdings in ArQule by 0.9% during the 2nd quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 1,385 shares during the last quarter. Point72 Asset Management L.P. bought a new position in ArQule during the 3rd quarter valued at about $2,220,000. Finally, First Eagle Investment Management LLC boosted its position in ArQule by 5.0% in the 3rd quarter. First Eagle Investment Management LLC now owns 12,438,996 shares of the biotechnology company’s stock valued at $13,807,000 after buying an additional 591,421 shares during the period. Institutional investors own 52.12% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.watchlistnews.com/arqule-arql-stock-price-up-12-1/1796661.html.

ArQule Company Profile

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with Analyst Ratings Network's FREE daily email newsletter.